The conversation desk
The conversations shaping women's health, who is taking part, and how funding, research and company activity are changing the debate.
Attributed perspectives alongside the funding, research and company developments shaping each question.
Longevity claims vs. evidence for women
Which longevity and peptide claims rest on evidence in women, and which do not?
Longevity products aimed at women are selling faster than trials in women are published. Contributors separate claims backed by data in women from those borrowed from studies in men or animals.
Where did women's health capital go?
Is women's health capital shrinking, consolidating, or moving to private and philanthropic money?
Founders, investors and analysts disagree on whether women's health funding is falling or simply changing hands. This page sets their views beside the financings OVUM has verified, so you can see who is writing the checks.
Is "femtech" still a useful category?
Does the femtech label help or hurt companies raising money and selling to health systems?
Some founders say the "femtech" label narrows their market and puts off health-system buyers; others say it gave the sector visibility. Contributors weigh in from fundraising and sales experience.
What AI actually changes in women's care
Where does AI improve diagnosis, caregiving or access, and where is it measurement theater?
AI tools are being pitched for diagnosis, triage and caregiving in women's health. Contributors separate measured improvements from products that only produce dashboards.
Is menopause care a business or a benefit?
Who pays for menopause care, and which models hold up beyond early adopters?
Employers, insurers and patients are each being asked to pay for menopause care. Contributors debate whether direct-to-consumer, employer-benefit or clinic models can grow past early adopters.
Fertility access and who pays
How are coverage, policy and advocacy changing access to fertility care?
IVF coverage, state and federal policy, and employer benefits decide who can afford fertility care. Contributors track what is changing and who is still left out.
Pelvic health and gynecological blind spots
Why do pelvic and gynecological conditions draw so little product and research investment?
Endometriosis, pelvic pain and other gynecological conditions affect millions of women yet draw little research money or new products. Contributors explain why, and what would change it.
Pregnancy as a cardiovascular stress test
What should change in care and products if pregnancy predicts later heart disease?
Complications such as preeclampsia and gestational diabetes signal higher heart risk years later. Contributors discuss what follow-up care, screening and products should look like.
The conversation reveals where the market is moving.
Compare who is advancing each view with the capital, research, policy and company moves around it. The strongest themes are those gaining evidence and execution—not attention alone.